MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Pevonedistat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2019 Planned End Date changed from 30 Sep 2021 to 23 Apr 2021.
- 02 Aug 2019 Planned primary completion date changed from 30 Sep 2021 to 23 Apr 2021.
- 02 Aug 2019 Status changed from not yet recruiting to recruiting.